UBS Group
BIB icon

UBS Group’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

UBS Group’s Portfolio BIB Stock Details BIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-200
Closed -$13K – 8818
2014
Q4 		$13K Buy
+200
New +$11.7K ﹤0.01% 8136

Other funds holding BIB

Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
CIA
Capital Investment Advisors Atlanta, Georgia $7.59B AUM 23.38% 1-Year Est. Return
KFS
Kaizen Financial Strategies Campbell, California $308M AUM 41.73% 1-Year Est. Return
PWM
Palumbo Wealth Management Great Neck, New York $478M AUM 50.95% 1-Year Est. Return
JF
Jump Financial Chicago, Illinois $12.4B AUM 62.79% 1-Year Est. Return
CIC
Chase Investment Counsel Charlottesville, Virginia $474M AUM 95.11% 1-Year Est. Return
TFA
Toth Financial Advisory Leesburg, Virginia $1.02B AUM 28.36% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.79B AUM 27.94% 1-Year Est. Return

UBS Group's BIB Position: Q2 2026 in Review

UBS Group held its ProShares Ultra NASDAQ Biotechnology (BIB) position steady in Q2 2026 at 1 share worth $101. The position accounts for ﹤0.01% of the portfolio, ranked #10105.

UBS Group first reported a position in BIB in Q4 2014 and has held it in 36 quarters since. The position peaked at $797K in Q3 2020. 20 funds tracked by Wall St. Rank hold BIB as of Q2 2026.

  • UBS Group held 1 share of ProShares Ultra NASDAQ Biotechnology worth $101 as of Q2 2026.
  • UBS Group left its ProShares Ultra NASDAQ Biotechnology share count unchanged in Q2 2026.
  • ProShares Ultra NASDAQ Biotechnology made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #10105 holding.
  • UBS Group first reported a position in ProShares Ultra NASDAQ Biotechnology in Q4 2014 and has held it in 36 quarters since.
  • UBS Group's ProShares Ultra NASDAQ Biotechnology position peaked at $797K in Q3 2020.
  • 20 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.